{"id":63746,"date":"2026-04-22T22:27:36","date_gmt":"2026-04-22T14:27:36","guid":{"rendered":"https:\/\/flcube.com\/?p=63746"},"modified":"2026-04-22T22:27:36","modified_gmt":"2026-04-22T14:27:36","slug":"roches-fenebrutinib-slashes-ms-relapse-rates-by-over-50-in-phase-iii-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63746","title":{"rendered":"Roche\u2019s Fenebrutinib Slashes MS Relapse Rates by Over 50% in Phase III Trials"},"content":{"rendered":"\n

Roche AG<\/strong> (SWX: ROP<\/a>, OTCMKTS: RHHBY<\/a>) announced that its investigational non-covalent Bruton\u2019s tyrosine kinase (BTK) inhibitor fenebrutinib<\/strong> met primary endpoints in both Phase III FENhance 1 and 2 studies<\/strong>, demonstrating unprecedented efficacy in relapsing multiple sclerosis (RMS)<\/strong>.<\/p>\n\n\n\n

Clinical Trial Results Summary<\/h2>\n\n\n\n
Trial<\/th>Treatment Duration<\/th>Comparator<\/th>ARR Reduction<\/th>Statistical Significance<\/th><\/tr><\/thead>
FENhance 1<\/strong><\/td>96 weeks<\/td>Teriflunomide<\/td>51.1%<\/td>p<0.001<\/td><\/tr>
FENhance 2<\/strong><\/td>96 weeks<\/td>Teriflunomide<\/td>58.5%<\/td>p<0.0001<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Both studies showed statistically significant and clinically meaningful reductions in annualized relapse rates (ARR) over 96 weeks of treatment compared to teriflunomide, a current standard-of-care oral therapy for RMS.<\/p>\n\n\n\n

Drug Mechanism & Differentiation<\/h2>\n\n\n\n